Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02012699 · ClinicalTrials.gov registry record
Integrated Cancer Repository for Cancer Research
A clinical trial of Lung Cancer and Pancreatic Cancer, sponsored by University of Nebraska.
- Recruiting
- Registry status
- 20
- Study locations
NCT02012699: Recruiting study of Lung Cancer and Pancreatic Cancer, sponsored by University of Nebraska.
NCT02012699 is a study of Lung Cancer and Pancreatic Cancer that is actively recruiting participants, run by University of Nebraska. The registry lists this as an open-ended (no fixed target) study. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02012699, a study of Lung Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- open-ended (no fixed target)
- Enrollment target
- 20
- Study locations
Study Summary
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.
Primary Outcome
This is a registry that will continue to accrue participants indefinitely.
Conditions Studied
Study Locations (20)
Florida
- Florida Hospital Memorial Medical Center - Daytona Beach
- Florida Hospital DeLand - DeLand
- Florida Hospital FISH - Orange City
- Florida Hospital Flagler - Palm Coast
- Tallahassee Memorial Hospital - Tallahassee
Minnesota
- Riverwood Healthcare Center - Aitkin
- Essentia Health-St. Joseph's Medical Center - Brainerd
- Essentia Health - Duluth Clinic - Duluth
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Rush-Copley Healthcare Center - Yorkville
Iowa
- Methodist Jennie Edmundson Hospital - Council Bluffs
- Covenant Medical Center, Inc - Waterloo
Maryland
- Northwest Hospital - Randallstown
- William E. Kahlert Regional Cancer Center - Westminster
Colorado
- Advent Health - Greenwood Village
Connecticut
- Prospect Medical Hospital - Manchester
Indiana
- Parkview Research Center - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | open-ended (no fixed target) |
| Start Date | 2013-11-01 |
| Est. Completion | 2099-12 |
What NCT02012699 shows while recruiting
NCT02012699 is an observational study that tracks outcomes without assigning an intervention. The registry lists this as an open-ended (no fixed target) study, common for long-running registries that collect data indefinitely.
The record links to 10 conditions, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02012699 names 20 study sites across 11 states, led by Florida, Minnesota, Illinois.
Frequently Asked Questions
What is clinical trial NCT02012699 about?
NCT02012699 is a clinical study titled "Integrated Cancer Repository for Cancer Research". The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct chara...
What is the current status of trial NCT02012699?
This trial is currently recruiting. The enrollment target is open-ended (no fixed target). The study started on 2013-11-01. Estimated completion is 2099-12.
What conditions does trial NCT02012699 study?
This clinical trial studies the following conditions: Lung Cancer, Pancreatic Cancer, Esophageal Cancer, Colon Cancer, Rectal Cancer.
Who is sponsoring clinical trial NCT02012699?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02012699 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI